ACE inhibitors reduce mortality, hospitalisation for congestive heart failure, and recurrent non-fatal myocardial infarction in people with left ventricular dysfunction after myocardial infarction.
A topic in Clinical Evidence 1 summarizes the evidence on ACE inhibitors in patients with myocardial infarction and left ventricular dysfunction. A systematic review of 3 RCTs (5,966 people). ACE inhibitors significantly reduced mortality (OR 0.74, 95% CI 0.66 to 0.83, NNT 17 during 2 years), hospitalisation for congestive heart failure (OR 0.73, 95% CI 0.63 to 0.85, NNT 28) and recurrent non-fatal myocardial infarction (OR 0.80, 95% CI 0.69 to 0.94, NNT 43).
The following decision support rules contain links to this evidence summary:
1. Sudlow C, Lonn E, Pignone M, Ness A, Rihal C. Secondary prevention of ischaemic cardiac events. Clin Evid 2002 Jun;(7):124-60. [PMID:12230641]
Copyright © 2019 Duodecim Medical Publications Limited.
ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction
is a sample topic from the Evidence-Based Medicine Guidelines
To view other topics, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.
"ACE Inhibitors for Secondary Prevention After Myocardial Infarction in Patients With Left Ventricular Dysfunction." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454601/all/ACE_inhibitors_for_secondary_prevention_after_myocardial_infarction_in_patients_with_left_ventricular_dysfunction.
ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/454601/all/ACE_inhibitors_for_secondary_prevention_after_myocardial_infarction_in_patients_with_left_ventricular_dysfunction. Accessed January 24, 2020.
ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/454601/all/ACE_inhibitors_for_secondary_prevention_after_myocardial_infarction_in_patients_with_left_ventricular_dysfunction
ACE Inhibitors for Secondary Prevention After Myocardial Infarction in Patients With Left Ventricular Dysfunction [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2020 January 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454601/all/ACE_inhibitors_for_secondary_prevention_after_myocardial_infarction_in_patients_with_left_ventricular_dysfunction.
TY - ELEC
T1 - ACE inhibitors for secondary prevention after myocardial infarction in patients with left ventricular dysfunction
ID - 454601
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454601/all/ACE_inhibitors_for_secondary_prevention_after_myocardial_infarction_in_patients_with_left_ventricular_dysfunction
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine